Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.
Jonathan L MettsWei XueZhengya GaoSara J IsraelsAaron R WeissRajkumar VenkatramaniDouglas J HarrisonPublished in: Pediatric blood & cancer (2024)
The prognosis of RRMS enrolled on single-agent phase II trials is poor. This pooled 6-month EFS of RRMS on single-agent trials may be used as a RRMS-specific benchmark for future single-agent phase II trials.